Lab
Labsolutions LLC
Labsolutions LLC was paid $1.76M by Medicaid between Jan 2018 and Sep 2019, across 136 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 14% of everything it billed.
33Billing provider infoLABSOLUTIONS LLC
ATLANTA, GA 30318
ATLANTA, GA 30318
33aNPI1275971707assigned 06/06/2013
33bProvider typeClinical Medical Laboratory
28Total paid$1.76M
24GClaims142,437
24DCodes billed136
24AFirst – last monthJan 2018 – Sep 2019
Compared with peers
Next to other Clinical Medical Laboratory providers in Georgia
Rank by total paid#19 of 66
Median peer was paid$178K
This provider vs. median9.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 98,400 | $1.20M | |
| 2019 | 44,037 | $566K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 14% | 3,726 | 3,153 | $251K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 10% | 12,546 | 8,822 | $181K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 10% | 11,272 | 8,079 | $176K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.5% | 3,186 | 2,477 | $62K |
| 81226 | 3.5% | 3,608 | 3,144 | $62K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.3% | 4,173 | 3,359 | $58K |
| 81225 | 3.0% | 3,245 | 2,846 | $53K | |
| 81479 | Unlisted molecular pathology procedure | 2.8% | 2,095 | 1,757 | $50K |
| 81201 | 2.8% | 812 | 683 | $50K | |
| 81408 | 2.8% | 357 | 307 | $49K | |
| 81406 | 2.4% | 1,244 | 1,042 | $42K | |
| 81405 | 2.3% | 1,253 | 1,049 | $41K |
124 more codes
| 81404 | 2.3% | 1,287 | $41K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.9% | 1,539 | $34K |
| 81317 | 1.9% | 813 | $33K | |
| 81335 | 1.8% | 2,402 | $32K | |
| 81230 | 1.5% | 1,935 | $27K | |
| 81231 | 1.5% | 1,938 | $27K | |
| 81401 | 1.5% | 2,037 | $26K | |
| 81381 | 1.5% | 1,958 | $26K | |
| 81403 | 1.3% | 874 | $22K | |
| 87486 | 1.2% | 3,733 | $22K | |
| 87581 | 1.2% | 3,732 | $22K | |
| 81328 | 1.2% | 1,624 | $21K | |
| 81241 | 1.1% | 1,942 | $20K | |
| 81232 | 1.0% | 1,634 | $18K | |
| 81291 | <1% | 2,645 | $17K | |
| 81227 | <1% | 2,368 | $16K | |
| 81240 | <1% | 1,948 | $16K | |
| 81242 | <1% | 483 | $13K | |
| 81355 | <1% | 1,869 | $12K | |
| 83970 | <1% | 1,636 | $11K | |
| 81292 | <1% | 397 | $10K | |
| 81321 | <1% | 389 | $9K | |
| 81214 | <1% | 392 | $9K | |
| 81298 | <1% | 376 | $9K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 487 | $9K |
| 84402 | <1% | 2,398 | $8K | |
| 82670 | <1% | 1,869 | $8K | |
| 81295 | <1% | 396 | $7K | |
| 82677 | <1% | 1,564 | $6K | |
| 82627 | <1% | 1,847 | $6K | |
| 84270 | <1% | 1,870 | $6K | |
| 81432 | <1% | 196 | $6K | |
| 84144 | <1% | 1,858 | $6K | |
| 81209 | <1% | 56 | $5K | |
| 81400 | <1% | 295 | $5K | |
| 84146 | <1% | 1,695 | $5K | |
| 83001 | <1% | 1,852 | $5K | |
| 83002 | <1% | 1,594 | $5K | |
| 82533 | <1% | 1,846 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,308 | $4K |
| 87481 | <1% | 359 | $4K | |
| 87530 | <1% | 280 | $4K | |
| 87529 | <1% | 340 | $4K | |
| 82607 | <1% | 1,623 | $3K | |
| 81407 | <1% | 73 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 376 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 376 | $3K |
| 82747 | <1% | 1,149 | $3K | |
| 84403 | <1% | 601 | $3K | |
| 86160 | <1% | 1,224 | $3K | |
| 87592 | <1% | 276 | $3K | |
| 87653 | <1% | 340 | $2K | |
| 87641 | <1% | 344 | $2K | |
| 81422 | <1% | 48 | $2K | |
| 87500 | <1% | 345 | $2K | |
| 87482 | <1% | 280 | $2K | |
| 84154 | <1% | 1,861 | $2K | |
| 87492 | <1% | 276 | $2K | |
| 87512 | <1% | 280 | $2K | |
| 84153 | <1% | 2,016 | $2K | |
| 87511 | <1% | 346 | $2K | |
| 87640 | <1% | 353 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 345 | $2K |
| 80061 | Lipid panel | <1% | 1,289 | $2K |
| 82728 | <1% | 1,035 | $2K | |
| 87799 | <1% | 283 | $2K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 48 | $2K |
| 84466 | <1% | 629 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,225 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 981 | $1K |
| 82390 | <1% | 613 | $1K | |
| 83003 | <1% | 312 | $1K | |
| 83516 | <1% | 681 | $1K | |
| 83540 | <1% | 1,493 | $1K | |
| 84702 | <1% | 329 | $1K | |
| 84481 | <1% | 539 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,189 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 990 | $957.44 |
| 81202 | <1% | 65 | $919.67 | |
| 80349 | <1% | 132 | $828.45 | |
| 82172 | <1% | 289 | $823.15 | |
| 83735 | <1% | 1,088 | $818.29 | |
| 84439 | <1% | 720 | $682.03 | |
| 82550 | <1% | 735 | $609.67 | |
| 83690 | <1% | 513 | $560.94 | |
| 82150 | <1% | 515 | $533.20 | |
| 80351 | <1% | 48 | $527.94 | |
| 80362 | <1% | 76 | $512.55 | |
| 84432 | <1% | 128 | $493.32 | |
| 83874 | <1% | 248 | $480.29 | |
| 80050 | General health panel | <1% | 306 | $471.56 |
| 84134 | <1% | 84 | $428.62 | |
| 83525 | <1% | 132 | $383.58 | |
| 81318 | <1% | 65 | $327.22 | |
| 83550 | <1% | 316 | $297.63 | |
| 80348 | <1% | 98 | $271.45 | |
| 83615 | <1% | 296 | $254.38 | |
| 82977 | <1% | 96 | $218.94 | |
| 84550 | <1% | 398 | $217.93 | |
| 80178 | <1% | 84 | $199.43 | |
| 86038 | <1% | 182 | $197.10 | |
| 86140 | <1% | 269 | $172.95 | |
| 80355 | <1% | 31 | $166.24 | |
| 84100 | <1% | 116 | $151.68 | |
| 82248 | <1% | 131 | $136.28 | |
| 83090 | <1% | 82 | $105.88 | |
| 83721 | <1% | 154 | $72.57 | |
| 86141 | <1% | 40 | $66.44 | |
| 85651 | <1% | 147 | $65.86 | |
| 86803 | <1% | 48 | $65.15 | |
| 86376 | <1% | 52 | $61.04 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29 | $54.13 |
| 84480 | <1% | 129 | $45.48 | |
| 82570 | <1% | 112 | $41.40 | |
| 83718 | <1% | 63 | $38.73 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 58 | $30.17 |
| 84478 | <1% | 63 | $27.21 | |
| 84436 | <1% | 147 | $25.28 | |
| 83986 | <1% | 112 | $22.32 | |
| 82465 | <1% | 63 | $20.52 | |
| 80076 | <1% | 29 | $11.32 | |
| 85652 | <1% | 15 | $5.51 | |
| 81003 | <1% | 15 | $4.32 | |
| 84066 | 0% | 172 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPATEL, MINAL (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Brighter Vision Eye Care, LLC | Philadelphia, PA | $91K |
| Wink Eye Care and Optical, LLC | Langhorne, PA | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.